Tuesday, October 1, 2019

Immunicom Finds $1.85M In Series B Funding

San Diego-based Immunicom, a developer of immunotherapy products for treating cancer, has raised $1.85M in its Series B funding, bringing the total raised in its Series B to $12.85M, the company said today. According to Immunicom, it has now raised $21.85M in total. Immunicom says it is developing a non-pharmaceutical solution for treating stage IV metastatic cancer. The company, led by founder and CEO Amir Jafri, has developed a blood-filtering technology, which the company says has the potential to treat a wide variety of cancer types; the company said that technology might also be applicable to treating inflammatory diseases and autoimmune diseases.